A prognostic analysis of patients with pathologic complete response after preoperative neoadjuvant chemoradiotherapy for locally advanced rectal cancer
Abstract： Objective To analyze the clinical factors for pathologic complete response (pCR) after preoperative neoadjuvant chemoradiotherapy (neo-CRT) for locally advanced rectal cancer. Methods From 2005 to 2012, 297 patients with locally advanced rectal cancer and complete clinical data were enrolled as subjects. Those patients were diagnosed with biopsy and treated with neo-CRT (radiotherapy by 3-dimonsional conformal radiotherapy or volumetric-modulated arc therapy) followed by radical surgery. The logistic regression model was used for the multivariate analyses of the correlation of pCR with age, gender, distance between tumor and the anal verge, serum level of carcinoembryonic antigen (CEA) before treatment, hemoglobin level before treatment, cT staging, and cN staging. Results In all patients, 78(26.7%) patients had pCR after treatment. The numbers of patients with pCR were 42(34.4%) in patients with stage T1-T3 disease and 37(21.1%) in patients with stage T4 disease. In the patients with serum CEA levels no higher than 5.33 ng/ml, 55(36.4%) had pCR after treatment, while in the patients with serum CEA levels higher than 5.33 ng/ml, only 24(16.4%) had pCR. The univariate analysis revealed that age, gender, distance between tumor and the anal verge, anemia before treatment, or cN staging were not related to pCR. The multivariate analysis showed that stage cT1-T3 and a serum CEA level no higher than 5.33 ng/ml before treatment were influencing factors for pCR after neo-CRT for locally advanced rectal cancer (P=0.031,P=0.000). Conclusions The clinical staging and the serum CEA level before treatment are influencing factors for pCR after neo-CRT for locally advanced rectal cancer. The serum CEA level before treatment can be considered as a predictor of pCR after neo-CRT for locally advanced rectal cancer.
Peng Haihua,Wang Chengtao,Yu Xin et al. A prognostic analysis of patients with pathologic complete response after preoperative neoadjuvant chemoradiotherapy for locally advanced rectal cancer[J]. Chinese Journal of Radiation Oncology, 2016, 25(10): 1079-1082.
[1] Sauer R,Becker H,Hohenberger W,et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer[J].N Engl J Med,2004,351(17):1731-1740.DOI:10.1056/ NEJMoa040694. [2] Martin ST,Heneghan HM,Winter DC.Systematic review and Meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer[J].Br J Surg,2012,99(7):918-928.DOI:10.1002/ bjs.8702. [3] Chan AKP,Wong A,Jenken D,et al. Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy[J].Int J Radiat Oncol Biol Phys,2005,61(3):665-677.DOI:10.1016/j.ijrobp.2004.06.206. [4] Stipa F,Chessin DB,Shia J,et al. A pathologic complete response of rectal cancer to preoperative combined-modality therapy results in improved oncological outcome compared with those who achieve no downstaging on the basis of preoperative Endorectal ultrasonography[J].Ann Surg Oncol,2006,13(8):1047-1053.DOI:10.1245/ASO.2006.03.053. [5] de Campos-Lobato LF,Stocchi L,Da Luz Moreira A,et al. Pathologic complete response after neoadjuvant treatment for rectal cancer decreases distant recurrence and could eradicate local recurrence[J].Ann Surg Oncol,2011,18(6):1590-1598.DOI:10.1245/s10434-010-1506-1. [6] Wen BX,Zhang LN,Wang CT,et al. Prognostic significance of clinical and pathological stages on locally advanced rectal carcinoma after neoadjuvant chemoradiotherapy[J].Radiat Oncol,2015,10:124.DOI:10.1186/s13014-015-0425-5. [7] Park IJ,You YN,Agarwal A,et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer[J].J Clin Oncol,2012,30(15):1770-1776.DOI:10.1200/JCO.2011.39.7901. [8] Wolthuis AM,Penninckx F,Haustermans K,et al. Outcome standards for an organ preservation strategy in stage Ⅱ and Ⅲrectal adenocarcinoma after neoadjuvant chemoradiation[J].Ann Surg Oncol,2011,18(3):684-690.DOI:10.1245/s10434-010-1324-5. [9] Gollins S,Myint AS,Haylock B,et al. Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer:impact on long-term clinical outcomes[J].J Clin Oncol,2011,29(8):1042-1049.DOI:10.1200/JCO.2010.29.7697. [10] Govindarajan A,Reidy D,Weiser M R,et al. Recurrence rates and prognostic factors in ypN0 rectal cancer after neoadjuvant chemoradiation and total mesorectal excision[J].Ann Surg Oncol,2011,18(13):3666-3672.DOI:10.1245/s10434-011-1788-y. [11] Belluco C,De Paoli A,Canzonieri V,et al. Long-term outcome of patients with complete pathologic response after neoadjuvant chemoradiation for cT3 rectal cancer:implications for local excision surgical strategies[J].Ann Surg Oncol,2011,18(13):3686-3693.DOI:10.1245/s10434-011-1822-0. [12] Kundel Y,Brenner R,Purim O,et al. Is local excision after complete pathological response to neoadjuvant chemoradiation for rectal cancer an acceptable treatment option?[J].Dis Colon Rectum,2010,53(12):1624-1631.DOI:10.1007/DCR.0b013e3181f5b64 d. [13] Callender GG,Das P,Rodriguez-Bigas MA,et al. Local excision after preoperative chemoradiation results in an equivalent outcome to total mesorectal excision in selected patients with T3 rectal cancer[J].Ann Surg Oncol,2010,17(2):441-447.DOI:10.1245/s10434-009-0735-7. [14] Tarantino I,Warschkow R,Worni M,et al. Elevated preoperative CEA is associated with worse survival in stage Ⅰ—Ⅲ rectal cancer patients[J].Br J Cancer,2012,107(2):266-274.DOI:10.1038/bjc.2012.267. [15] Song SS,Hong JC,McDonnell SE,et al. Combined modality therapy for rectal cancer:the relative value of posttreatment versus pretreatment CEA as a prognostic marker for disease recurrence[J].Ann Surg Oncol,2012,19(8):2471-2476.DOI:10.1245/s10434-012-2266-x. [16] Das P,Skibber JM,Rodriguez-Bigas MA,et al. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer[J].Cancer,2007,109(9):1750-1755.DOI:10.1002/cncr.22625. [17] Moureau-Zabotto L,Farnault B,de Chaisemartin C,et al. Predictive factors of tumor response after neoadjuvant chemoradiation for locally advanced rectal cancer[J].Int J Radiat Oncol Biol Phys,2011,80(2):483-491.DOI:10.1016/j.ijrobp.2010.02.025. [18] Steinhagen E,Shia J,Riedel E,et al. Response to neoadjuvant therapy in patients with early age-of-onset rectal cancer[J].Dis Colon Rectum,2013,56(1):58-63.DOI:10.1097/DCR.0b013e3182707e47. [19] R del C,Martus P,Papadoupolos T,et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer[J].J Clin Oncol,2005,23(34):8688-8696.DOI:10.1200/JCO.2005.02.1329.
2016, Vol. 25 
